New immune combo shows promise against stubborn lymphoma

NCT ID NCT03349450

First seen May 07, 2026 · Last updated Jun 13, 2026 · Updated 10 times

Summary

This study tested a combination of three drugs (DPX-Survivac, low-dose cyclophosphamide, and pembrolizumab) in 25 adults with diffuse large B-cell lymphoma that had come back or not responded to previous treatments. The goal was to see if the immune system could be boosted to shrink tumors. The treatment was given for up to one year, and participants were monitored for side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, B3H 2Y9, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre, Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Tom Baker Cancer Centre - Alberta Health Services

    Calgary, Alberta, Canada

Conditions

Explore the condition pages connected to this study.